Log in

NASDAQ:SURF - Surface Oncology Stock Price, Forecast & News

$1.84
-0.23 (-11.11 %)
(As of 12/12/2019 06:13 AM ET)
Today's Range
$1.81
Now: $1.84
$2.10
50-Day Range
$1.35
MA: $1.83
$2.34
52-Week Range
$1.15
Now: $1.84
$9.08
Volume182,500 shs
Average Volume68,744 shs
Market Capitalization$51.30 million
P/E RatioN/A
Dividend YieldN/A
Beta2.54
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SURF
CUSIPN/A
CIKN/A
Phone617-714-4096

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.42 million
Book Value$3.72 per share

Profitability

Net Income$-6,600,000.00
Net Margins-176.50%

Miscellaneous

Employees76
Market Cap$51.30 million
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable

Receive SURF News and Ratings via Email

Sign-up to receive the latest news and ratings for SURF and its competitors with MarketBeat's FREE daily newsletter.


Surface Oncology (NASDAQ:SURF) Frequently Asked Questions

What is Surface Oncology's stock symbol?

Surface Oncology trades on the NASDAQ under the ticker symbol "SURF."

How were Surface Oncology's earnings last quarter?

Surface Oncology Inc (NASDAQ:SURF) posted its earnings results on Tuesday, November, 12th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by $0.03. The company earned $0.34 million during the quarter, compared to analysts' expectations of $2.50 million. Surface Oncology had a negative net margin of 176.50% and a negative return on equity of 48.88%. View Surface Oncology's Earnings History.

When is Surface Oncology's next earnings date?

Surface Oncology is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Surface Oncology.

What is the consensus analysts' recommendation for Surface Oncology?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Surface Oncology.

Has Surface Oncology been receiving favorable news coverage?

News stories about SURF stock have trended negative this week, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Surface Oncology earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Surface Oncology.

Are investors shorting Surface Oncology?

Surface Oncology saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 214,500 shares, an increase of 20.1% from the November 14th total of 178,600 shares. Based on an average trading volume of 91,000 shares, the days-to-cover ratio is currently 2.4 days. Currently, 1.4% of the company's shares are sold short. View Surface Oncology's Current Options Chain.

Who are some of Surface Oncology's key competitors?

What other stocks do shareholders of Surface Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include FedEx (FDX), AT&T (T), Visa (V), Allena Pharmaceuticals (ALNA), Alliance Data Systems (ADS), Anadarko Petroleum (APC), Chevron (CVX), Medtronic (MDT), Altria Group (MO) and 22nd Century Group (XXII).

Who are Surface Oncology's key executives?

Surface Oncology's management team includes the folowing people:
  • Mr. Daniel S. Lynch, Exec. Chairman (Age 61)
  • Mr. J. Jeffrey Goater, CEO, Pres & Director (Age 44)
  • Dr. Vito J. Palombella, Chief Scientific Officer (Age 56)
  • Dr. Robert W. Ross, Chief Medical Officer (Age 45)
  • Ms. Jessica Fees, Sr. VP of Fin. & Bus. Operations and Treasurer (Age 47)

When did Surface Oncology IPO?

(SURF) raised $84 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI served as the underwriters for the IPO.

Who are Surface Oncology's major shareholders?

Surface Oncology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.76%) and Tower Research Capital LLC TRC (0.09%). Company insiders that own Surface Oncology stock include David S Grayzel and Lilly Ventures Fund I Llc. View Institutional Ownership Trends for Surface Oncology.

Which major investors are buying Surface Oncology stock?

SURF stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC and Tower Research Capital LLC TRC. Company insiders that have bought Surface Oncology stock in the last two years include David S Grayzel and Lilly Ventures Fund I Llc. View Insider Buying and Selling for Surface Oncology.

How do I buy shares of Surface Oncology?

Shares of SURF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Surface Oncology's stock price today?

One share of SURF stock can currently be purchased for approximately $1.84.

How big of a company is Surface Oncology?

Surface Oncology has a market capitalization of $51.30 million and generates $59.42 million in revenue each year. The company earns $-6,600,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Surface Oncology employs 76 workers across the globe.View Additional Information About Surface Oncology.

What is Surface Oncology's official website?

The official website for Surface Oncology is http://www.surfaceoncology.com/.

How can I contact Surface Oncology?

Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-4096 or via email at [email protected]


MarketBeat Community Rating for Surface Oncology (NASDAQ SURF)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  249
MarketBeat's community ratings are surveys of what our community members think about Surface Oncology and other stocks. Vote "Outperform" if you believe SURF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SURF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel